Baseline characteristics of 360 patients with preterm birth managed for both phases of the audit in Mulago National Referral Hospital labor ward.

Baseline characteristics of 360 patients with preterm birth managed for both phases of the audit in Mulago National Referral Hospital labor ward.</p

Findings from baseline audit as per guidelines by Delphi technique for preterm birth management.

Findings from baseline audit as per guidelines by Delphi technique for preterm birth management.</p

A comparison of the baseline and second audit for preterm birth management as per the developed protocol.

A comparison of the baseline and second audit for preterm birth management as per the developed protocol.</p

Audit cycle.

BackgroundPreterm birth is the leading cause of neonatal deaths and the second leading cause of death in children under five after pneumonia. The study aimed at improving the management of preterm birth through the development of protocols for standardization of care.MethodsThe study was conducted in Mulago National Referral Labor ward in two phases. A total of 360 case files were reviewed and mothers whose files had missing data interviewed for clarity for both the baseline audit and the re-audit. Chi squares were used to compare results for the baseline and the re-audit.ResultsThere was significant improvement in four parameters out of the six that were used to assess quality of care and these were 32% increase in administration of Dexamethasone for fetal lung maturity, 27% increase in administration of Magnesium Sulphate for fetal neuroprotection and 23% increase in anti-biotic administration. A 14% reduction noted in patients who received no intervention. However, there was no change in the administration of Tocolytic.ConclusionThe results of this study have shown that protocols standardize care and improve the quality of care in preterm delivery to optimize outcomes.</div

Data from: Umbilical vein oxytocin for the treatment of retained placenta (Release Study).

This is a fully labelled SPSS dataset from the clinical trial of umbilical oxytocin for the treatment of human retained placentas. Ethical approval for its publication was obtained from the Central NRES Committee (London) on 24th March 2015. All except 2 indirect identifiers have been removed so as to fully anonymise it in line with recommendations from Hrynaszkiewicz et al (BMJ 2010;340:c181)